• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    4/5/24 12:31:08 PM ET
    $ACOR
    $AIH
    $BIAF
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Health Care
    Get the next $ACOR alert in real time by email

    Gainers

    • Candel Therapeutics (NASDAQ:CADL) stock increased by 27.6% to $8.17 during Friday's regular session. The company's market cap stands at $239.6 million.
    • Galectin Therapeutics (NASDAQ:GALT) shares increased by 20.66% to $3.62. The company's market cap stands at $224.0 million.
    • Ocugen (NASDAQ:OCGN) stock moved upwards by 17.88% to $1.78. The company's market cap stands at $456.7 million. As per the press release, Q4 earnings came out 3 days ago.
    • Processa Pharma (NASDAQ:PCSA) shares moved upwards by 17.67% to $2.73. The market value of their outstanding shares is at $4.6 million.
    • bioAffinity Technologies (NASDAQ:BIAF) stock rose 15.5% to $2.98. The market value of their outstanding shares is at $33.1 million. The company's, Q4 earnings came out 4 days ago.
    • GlucoTrack (NASDAQ:GCTK) shares moved upwards by 15.2% to $0.46. The company's market cap stands at $12.3 million.

    Losers

    • Acorda Therapeutics (NASDAQ:ACOR) stock decreased by 17.1% to $1.39 during Friday's regular session. The market value of their outstanding shares is at $1.7 million. As per the press release, Q4 earnings came out 4 days ago.
    • Aesthetic Medical Intl (NASDAQ:AIH) shares fell 16.83% to $0.43. The market value of their outstanding shares is at $20.2 million.
    • Ontrak (NASDAQ:OTRK) stock declined by 15.39% to $0.33. The market value of their outstanding shares is at $14.0 million.
    • Kintara Therapeutics (NASDAQ:KTRA) shares fell 15.25% to $0.12. The market value of their outstanding shares is at $4.7 million.
    • Trxade Health (NASDAQ:MEDS) shares declined by 14.33% to $8.67. The company's market cap stands at $10.4 million.
    • eFFECTOR Therapeutics (NASDAQ:EFTR) stock fell 13.86% to $2.55. The company's market cap stands at $9.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $AIH
    $BIAF
    $CADL

    CompanyDatePrice TargetRatingAnalyst
    Candel Therapeutics Inc.
    $CADL
    10/28/2025$15.00Overweight
    Stephens
    Candel Therapeutics Inc.
    $CADL
    9/3/2025$7.00Buy → Neutral
    BofA Securities
    Candel Therapeutics Inc.
    $CADL
    6/30/2025$23.00Buy
    H.C. Wainwright
    Galectin Therapeutics Inc.
    $GALT
    6/17/2025$6.00Buy
    H.C. Wainwright
    Candel Therapeutics Inc.
    $CADL
    2/20/2025$25.00Buy
    Citigroup
    Candel Therapeutics Inc.
    $CADL
    2/19/2025$20.00Buy
    Canaccord Genuity
    Candel Therapeutics Inc.
    $CADL
    2/7/2025$15.00Buy
    BofA Securities
    Ocugen Inc.
    $OCGN
    10/15/2024$4.00Buy
    Maxim Group
    More analyst ratings

    $ACOR
    $AIH
    $BIAF
    $CADL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Johnson-Greene Treerita Essalima claimed ownership of 500,350 shares (SEC Form 3)

    3 - Ocugen, Inc. (0001372299) (Issuer)

    3/5/26 9:27:38 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Manning Paul B bought $2,999,996 worth of shares (550,458 units at $5.45) (SEC Form 4)

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    2/26/26 7:38:59 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Eldred Kary bought $810 worth of shares (300 units at $2.70), increasing direct ownership by 0.46% to 65,682 units (SEC Form 4)

    4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)

    2/9/26 4:25:19 PM ET
    $GALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AIH
    $BIAF
    $CADL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manning Paul B bought $2,999,996 worth of shares (550,458 units at $5.45) (SEC Form 4)

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    2/26/26 7:38:59 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Eldred Kary bought $810 worth of shares (300 units at $2.70), increasing direct ownership by 0.46% to 65,682 units (SEC Form 4)

    4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)

    2/9/26 4:25:19 PM ET
    $GALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Freeman Kevin D bought $19,514 worth of shares (5,500 units at $3.55), increasing direct ownership by 11% to 55,269 units (SEC Form 4)

    4/A - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)

    12/23/25 1:21:11 PM ET
    $GALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AIH
    $BIAF
    $CADL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

    NEEDHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for oral presentation in the Practice-changing, Paradigm-shifting Clinical Trials in Urology session, as part of the American Urological Association (AUA) 2026 Annual Meeting Plenary Program being held in Washington D.C. from May 15-18, 2026. The presentation will feature new data from the Company's phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with interm

    3/9/26 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

    Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected in the first quarter 2027, advancing OCU400 towards potential approval in 2027.OCU410ST Phase 2/3 pivotal confirmatory trial nearing enrollment completion. Interim data expected in the third quarter 2026, followed by topline Phase 2/3 data in the second quarter 2027 in advance of the BLA submission.OCU410 positive preliminary Phase 2 data announced in January. Full Phase 2 data expected in March 2026. First regional licensing agreement for OCU400 in 2025 initiates strategic partnership strategy

    3/4/26 8:15:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

    Next-generation cellular therapies and regenerative medicine drive exponential expansionNEW YORK, March 3, 2026 /CNW/ -- Market News Updates News Commentary - The global anti-aging therapy market is gaining serious momentum as people live longer and actively look for ways to stay healthier, more energetic, and more youthful. What was once considered a niche cosmetic category has evolved into a major healthcare and biotech opportunity. Industry forecasts project the broader anti-aging market could surpass $420 billion by 2030, growing at an estimated 8–9% compound annual growth rate (CAGR). This growth is being fueled by rising healthcare awareness, advances in biotechnology, and increased de

    3/3/26 9:00:00 AM ET
    $GERN
    $NAGE
    $NTLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $ACOR
    $AIH
    $BIAF
    $CADL
    SEC Filings

    View All

    bioAffinity Technologies Inc. filed SEC Form 8-K: Leadership Update

    8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

    3/6/26 4:30:39 PM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form PRE 14A filed by bioAffinity Technologies Inc.

    PRE 14A - bioAffinity Technologies, Inc. (0001712762) (Filer)

    3/5/26 5:17:16 PM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form S-8 filed by Ocugen Inc.

    S-8 - Ocugen, Inc. (0001372299) (Filer)

    3/4/26 12:23:26 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AIH
    $BIAF
    $CADL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens initiated coverage on Candel Therapeutics with a new price target

    Stephens initiated coverage of Candel Therapeutics with a rating of Overweight and set a new price target of $15.00

    10/28/25 8:02:46 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Candel Therapeutics from Buy to Neutral and set a new price target of $7.00

    9/3/25 8:04:26 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Candel Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Candel Therapeutics with a rating of Buy and set a new price target of $23.00

    6/30/25 7:59:11 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AIH
    $BIAF
    $CADL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ontrak Inc.

    SC 13G/A - Ontrak, Inc. (0001136174) (Subject)

    11/14/24 4:24:03 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

    SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

    11/12/24 4:59:47 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AIH
    $BIAF
    $CADL
    Leadership Updates

    Live Leadership Updates

    View All

    bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board

    Advisory Board provides independent guidance on strategic priorities, including growing adoption of the Company's noninvasive CyPath® Lung diagnostic test bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced new appointments to its Medical and Scientific Advisory Board, welcoming David Ost, MD, MPH, University of Texas MD Anderson Cancer Center, Daniel Sterman, MD, New York University Langone Medical Center, and J. Scott Ferguson, MD, University of Wisconsin School of Medicine and Public Health, to its panel of recognized leaders in the field. The appointments reflect a planned expans

    2/9/26 8:00:00 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

    MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this

    2/9/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights

    Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expert, Usman Latif, MD, MBA Strengthened balance sheet, cash and cash equivalents expected to fund operations through March 2026, including long-term feasibility clinical trials and achievement of related milestones Rutherford, NJ, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results

    11/13/25 4:05:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $ACOR
    $AIH
    $BIAF
    $CADL
    Financials

    Live finance-specific insights

    View All

    Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results

    MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 3029428Webcast: Available on the events sec

    2/18/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

    MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with KOLs and Ocugen executive leadership to discuss data from the first half of patients completing one year since treatment in the OCU410 Phase 2 ArMaDa clinical trial at 8:30 a.m. ET on Thursday, January 15, 2026. Study investigators leading the webcast include: Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates and Clinical Professor at the University of Nevada, Reno School

    1/13/26 7:00:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update

    NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and nine months ended September 30, 2025. "The new NAVIGATE data presented at AASLD further strengthen the clinical and mechanistic profile of belapectin. We continue to see encouraging consistency across key biomarkers—including FibroScan®, ELF, and PRO-C3—all supporting belapectin's durable antifibrotic activity and potential to slow disease progression in patients with compensated MASH cirrhosis. We submitted the NAVIGATE data package to the FDA and r

    11/14/25 8:00:00 AM ET
    $GALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AIH
    $BIAF
    $CADL
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Galectin Therapeutics Inc. on Jun 20

    Recently, on June 20, 2024, Galectin Therapeutics Inc. saw an insider purchase by Director Freeman Kevin D. He bought $5,950 worth of shares, which amounted to 2,500 units at a price of $2.38 per share. This transaction increased his direct ownership by 10% to 28,469 units, as reported in the SEC Form 4. It's essential to analyze this insider purchase in the context of previous transactions within the company. On February 7, 2024, Uihlein Richard E was granted 23,256 shares, increasing his direct ownership by 0.23% to 10,268,751 units. Similarly, on the same date, Zordani Richard A. Jr. filed an SEC Form 4. Continuing the trend, a new insider, Carson Benjamin Sr, filed an SEC Form 3 on Febr

    6/20/24 6:44:03 PM ET
    $GALT
    Biotechnology: Pharmaceutical Preparations
    Health Care